The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW  was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.

During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat

Nadia Merad Coliac, plastic designer, joined the NOSE (Nasal Olfactory Stemness and Epigenesis) team, as an Associate researcher. At the crossroads of several disciplines, she develops an experimental work of art and science, in the field of bioluminescence. She is considering a therapeutic application in patients with autism spectrum disorders (ASD). Recently, Nadia published Lumière vivante - Théorie et pratique de la bioluminescence (Living light - theory and use of bioluminescence) - L’Harmattan eds.

We obtained results showing the crucial role of the A2B5 epitope in the promotion of proliferation, migration, clonogenicity, and tumorigenesis of glioblastoma cells, indicating that the glycolipids recognized by the A2B5 antibody are attractive targets for glioblastoma therapy.

Many members of the INP attended the annual Canceropole PACA meeting in the Palais des Congrès of St Raphaël on the 4th and 5th of july. In the frame of the translational research call, F. Devred (INP team 9) & E. Tabouret (INP team 8) presented the results and perspective of their project "Next generation plasma profiling of gliomas using nanoDSF: toward a new prognostic and monitoring tool"

Full program available here.

INP team 8 and 9 and PINT members being part of the French Microtubule Network, several members presented their work at the 4th French Microtubule Network gathering in Rennes on the 1srt and 2nd july 2019, in the  "Microtubules and their regulators : new therapeutic targets" session and the "Microtubules, assembly and regulation" session.

An article entitled "Le CNRS et Aix-Marseille Université signent un accord avec la PME Vect-Horus sur la propriété intellectuelle",  published in the CNRS Innovation Letter of 20 June 2019 and relayed by the INSB site, features the agreement signed by CNRS, AMU and Vect-Horus establishing the intellectual property rights regime and the exploitation of patents.

Our last work on IAPs : "Inhibitor of Apoptosis Proteins (IAPs) Determines Glioblastoma Stem‐Like Cell Fate in an Oxygen‐Dependent Manner" is now published in Stem Cells. We highlighted that pharmacological inhibition of IAPs by Smac mimetic GDC-0152 was able to decrease glioblastoma stem-like cells viability in hypoxia by decreasing cell proliferation and increasing apoptosis through ATR and TNFα pathways

During the last NeuroFrance congress held from May 22 to 24, 2019 at the Palais des Congrès in Marseille, the INP distinguished itself through 20 posters, 4 oral communications, and 1 symposium moderation, not to mention the organization of the "Art in Mind" exhibition, showing not only the richness and quality of his research but also his open-mindedness. 

In the CNRS Innovation Letter of April, there is an article entitled "Des molécules vectorisées pour cibler les maladies neurodégénératives" featuring the research collaboration agreement signed by Vect-Horus and Johnson & Johnson subsidiary Janssen Pharmaceuticals for treating neurodegenerative diseases.